Embracing Future Holdings Limited · SGX:8YY
Embracing Future — Biolidics — Shareholder Meeting (2019)
14 slides from Embracing Future's shareholder meeting presentation, 2019
Slide 1: Corporate Presentation – Annual General Meeting 2019
CORPORATE PRESENTATION ANNUAL GENERAL MEETING 2019
Slide 2: Important Notice
Important Notice Bringing Clarity to Cancer Biolidics Limited is a company listed on the Catalist Board of the Singapore Exchange Securities Trading Limited (the “SGX-ST”). This presentation has been prepared by the Company and its contents have been reviewed by the Company’s sponsor, United Oversea
Slide 3: A Global Healthcare Problem
A Global Healthcare Problem Bringing Clarity to Cancer Cancer is the second Metastasis is responsible for an leading cause of death globally and is responsible for estimated 90% of cancer deaths an estimated 9.6 million It is the process by which cancer cells spread through the blood and deaths in 2
Slide 4: Limitations of Traditional Diagnostic Methods
Limitations of Traditional Diagnostic Methods Bringing Clarity to Cancer Cancer is difficult to diagnose and manage due to its heterogeneity at morphological, genetic and clinical levels Traditional Diagnostic Involve a tissue biopsy, or the surgical removal of tissue from a patient's body and the t
Slide 5: Novel Patented Technology
Novel Patented Technology Bringing Clarity to Cancer Up to 70% of medical decisions are based on laboratory tests* Biolidics has strong potential to revolutionise the cancer diagnostics market Dean Flow Fractionation Microfluidics ctDNA? 7.5ml blood sample is Red blood cell CTC enrichment is Enriche
Slide 6: Global Liquid Biopsy Prospects
Global Liquid Biopsy Prospects Bringing Clarity to Cancer Increased Prevalence of Cancer The global market for cancer diagnostics, in • In Asia, dietary changes coupled with the increasing and aging population, have resulted in an increase which we operate, is expected to grow at a in the rates of c
Slide 7: Cancer Diagnostics Market in China
Cancer Diagnostics Market in China Bringing Clarity to Cancer Type of Forecasted Revenue Forecasted Revenue Cancer in 2019* in 2023* The Liquid Biopsy Market in China is Lung US$22.7 million US$59.6 million estimated to grow from US$195.4 million in 2019 to Breast US$17.5 million US$59.0 million US$
Slide 8: Business Model
Business Model Bringing Clarity to Cancer Sale of our Sale of the accompanying CTChip® Development of a wide range of ClearCell® FX1 System FR1 biochip and other clinical or laboratory developed consumables tests Each CTChip® FR1 biochip can be only used for one-time liquid biopsy test Higher sales
Slide 9: Strategic Collaboration with Sysmex
Strategic Collaboration with Sysmex Bringing Clarity to Cancer Announced on 20 February 2019 Sysmex is listed on the Tokyo Stock Exchange with a market capital of approximately S$17 billion as at 18 February 2019. • Biolidics and Japan-based Sysmex Corporation (“Sysmex”) to jointly collaborate and d
Slide 10: Corporate Milestones Since IPO
Corporate Milestones Since IPO Bringing Clarity to Cancer Mar 19 - Achieves improved performance in FY2018 Focus on the development of a • Healthy balance sheet with cash and cash equivalents of S$11.5 wide range of clinical or million and no debt laboratory developed tests • Strong technology leade
Slide 11: Summary
Summary Bringing Clarity to Cancer 1. Strong Prospects for Liquid Biopsy Market Increased prevalence of cancer Advantages of a simple blood test (minimally invasive) vs. tissue biopsy (invasive). Recurring and need to be monitored over time The global market for cancer diagnostics, in which we
Slide 12: Thank You
Bringing Clarity to Cancer THANK YOU ANNUAL GENERAL MEETING 2019 12
Slide 13: Overview
Overview Bringing Clarity to Cancer Corporate Profile Novel Patented Technology • Incorporated in 2009 and based in Singapore, Biolidics Biolidics ClearCell® FX1 System allows users of the Limited (“Biolidics” or “the Company”) is a medical technology system to perform liquid biopsies to test for th
Slide 14: Key Team
Key Team Bringing Clarity to Cancer Mr. Jeremy Yee Mr. Johnson Chen Non-Executive Non-Independent Chairman Non-Executive Non-Independent Director Currently the Executive Director and Chief Executive Officer Currently the Non-Executive Non-Independent Chairman of of Clearbridge Health Limited, a